Cambium Bio (ASX:CMB) Days Payable: 0.00 (As of Dec. 2025)

What is Cambium Bio Days Payable?

Cambium Bio ASX:CMB -6.74% 35 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 707 Biotechnology companies, Cambium Bio ranks worse than 141442.57% on this metric.

Cambium Bio's average Accounts Payable for the six months ended in Dec. 2025 was A$0.53 Mil. Cambium Bio's Cost of Goods Sold for the six months ended in Dec. 2025 was A$0.00 Mil.

The historical rank and industry rank for Cambium Bio's Days Payable or its related term are showing as below:

ASX:CMB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Cambium Bio's Days Payable stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Cambium Bio Days Payable Related Terms

Cambium Bio Days Payable Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Days Payable Chart

Cambium Bio Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Days Payable

Get a 7-Day Free Trial

0.00

Cambium Bio Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

ASX:CMB vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Cambium Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Days Payable distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Days Payable falls into.

Save Embed

35GF Score

Cambium Bio Ltd ASX:CMB

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cambium Bio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Cambium Bio's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as

	Days Payable (A: Jun. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2024 )	+	Accounts Payable (A: Jun. 2025 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2025 )	*	Days in Period
=	( (1.221	+	0.596)	/	2 )	/	0	*	365
=	0.9085					/	0	*	365
=	N/A

Cambium Bio's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

	Days Payable (Q: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2025 )	+	Accounts Payable (Q: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2025 )	*	Days in Period
=	( (0.596	+	0.464)	/	2 )	/	0	*	365 / 2
=	0.53					/	0	*	365 / 2
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Cambium Bio (ASX:CMB) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #999999 out of 707 companies in the Biotechnology industry.

Is Cambium Bio's Days Payable too high?

Cambium Bio's current Days Payable is 0.00. Based on the distribution chart, Cambium Bio ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does Cambium Bio's Days Payable compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Cambium Bio ranks #999999 out of 707 companies for Days Payable. This places Cambium Bio in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cambium Bio stock overvalued right now?

Cambium Bio (ASX:CMB) has a current Days Payable of 0.00. The current Days Payable is 0.00. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:1AD ASX:IMC ASX:RNV ASX:BGT ASX:AGN ASX:IXC ASX:NTI ASX:VBS ASX:TRP ASX:NX1 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153

Website https://www.cambium.bio

Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

35GF Score

Get the complete analysis for ASX:CMB

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42

Price

View ASX:CMB Analysis

See Days Payable data for all stocks →